Embedded Files
Zhan Qi-Xian
Honorary Doctorate in Public Health, Johns Hopkins University
Medical degree, Sun Yat-sen Medical College
Current Positions:
Current Positions:
Chairman, Adimmune Corporation
Chairman, Medical Care Education and Career Development Committee, Tzu Chi Foundation
Past Positions:
Past Positions:
Superintendent, Chang Gung Memorial Hospital
Chairman of the Board, Chung-Hua Min Sheng Hospital
Minister of Health, Executive Yuan
Chairman of the Board, National Health Research Institutes
Secretary-General, Executive Yuan
詹啟賢
約翰霍普金斯大學公共衛生榮譽博士學位
中山醫學院醫學系
目前職位：
阿迪免疫公司董事長
慈濟基金會醫療教育與職業發展委員會主席
過去的職位：
長庚紀念醫院院長
中華民生醫院董事長
行政院衛生部長
國家衛生研究院董事會主席
行政院秘書長
Introduction film of Zhan Qi-Xian www.youtube.com/watch?v=zo2lwhxX8wI
From the upstream, we see three primary sources: raw material suppliers, labor suppliers, and equipment providers. These three generate upstream waste materials, which are divided into two types: non-hazardous and hazardous waste.
For non-hazardous waste, 94.82% consists of animal-derived waste. Other non-hazardous wastes include activated carbon and waste oils.
As for hazardous waste it includes chemical-laden materials or abandoned containers, expired medicines, sharp medical instruments like needles, and contaminated mixed waste at 2.79%.
Next, the downstream processing. For non-hazardous waste, 94.82% is subjected to incineration, as it cannot be recycled. The others are either reused or undergo other treatments.
Hazardous waste, however, requires more specific handling. The majority would go through incineration as well, which ensures safe disposal for the environment and public health.
從上游開始，我們看到三個主要來源：原料供應商、勞動力供應商和設備供應商。這三者產生上游廢棄物，分為無害廢棄物和有害廢棄物兩類。
對於無害廢棄物，94.82%是動物性廢棄物。其他無害廢棄物包括反應污泥；廢油。
危險廢棄物包括化學物質或廢棄容器、過期藥品、針頭等尖銳醫療器材和受污染的混合廢棄物（2.79%）。
其次，進行下游加工。對於無害廢棄物，94.82%會被焚燒，因為無法回收。餘下被重複使用或進行其他處理。
最後，4.75%的危險物質被焚燒。
In 2022, Adimmune Corporation generated a total of 531.15 tons of waste, approximately 17% less than the previous year.
2022 年，國光生技所產生的廢棄物共計 531.15 噸，較去年減少約 17%。
In 2022, Adimmune Corporation's energy intensity and greenhouse gas emission intensity decreased by approximately 11.24% and 11.11%, respectively, compared to 2021.
2022年國光生計產生的能源密集度、溫室氣體排放密集度較 2021 年分別減少了約 11.24% 及 11.11% 。
Deputy General Manager of Quality Assurance
邱進益 (Chiu Chin-Yi)
Ph.D. in Molecular Biology, University of Maryland, USA
Past Positions:
Past Positions:
Head of Pharmaceutical Management and Acting Director of the Food and Drug Testing Bureau at the Taiwan FDA
Board member of the Taiwan Pharmaceutical Manufacture and Development Association
品保副總經理 邱進益 (Chiu Chin-Yi)
博士美國馬裡蘭大學分子生物學博士
過去的職位：
台灣食品藥物管理局藥品管理處處長, 食品藥物檢驗局局長
台灣醫藥製造發展同業公會理事
Our company efficiently manages water with an innovative recycling system.
Tap water undergoes Reverse Osmosis (RO) purification, producing ultra-pure water while collecting ROR (reject water) for recycling.
Purified water then splits into two paths: one goes through a soft water system to prevent scaling, and the other supplies general use.
Used water is treated at a wastewater facility for discharge or recycling.
Future plans include capturing evaporated water from cooling towers.
This system supports ESG goals, addressing Taiwan’s water scarcity and promoting sustainability.
我們公司透過創新的回收系統有效地管理水。
自來水經過逆滲透（RO）淨化，產生超純水，同時收集ROR（廢水）進行循環使用。
然後淨化水分成兩條路徑：一條經過軟水系統以防止結垢，另一條則供應一般用途。
用過的水在廢水處理設施中處理以便排放或回收。
未來的計劃包括收集冷卻水塔中的蒸發水。
該系統支持 ESG 目標，解決台灣的水資源短缺並促進永續發展。
Precipitation in Taiwan is uneven in time and space, and climate change has exacerbated water shortages. Guoguang Biotechnology uses recycling systems and water-saving measures to reduce costs and improve water use efficiency and company resilience.
台灣降水時空不均，氣候變遷加劇缺水問題，國光生技透過回收系統與節水措施，降低成本並提升用水效率及公司韌性。
Guoguang Biotech treats wastewater in accordance with the Water Pollution Prevention and Control Act and other regulations. The average daily volume is about 434 cubic meters, and the water quality meets the standard and is lower than the legal limit.
國光生技依《水污染防治法》等規範處理廢水，日均量約434立方公尺，水質達標低於法定限值。
Sources:
Adimmune ESG Report 2022 www.adimmune.com.tw/uploads/images/adimmuneESG2022.pdf
Adimmune ESG Report 2023 www.adimmune.com.tw/uploads/images/adimmuneESG2023.pdf
Introduction to the CEO www.adimmune.com.tw/tw/about/executive
Introduction to Vice President of Quality Assurance Department www.adimmune.com.tw/tw/about/executive
Page updated
Google Sites
Report abuse